US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Enliven Treateutics

61.15

+1.332.22%

Post-market: 61.900.7500+1.23%17:01 EDT

Volume:1.26M

Turnover:76.12M

Market Cap:4.48B

PE:-36.50

High:61.99

Open:59.77

Low:59.47

Close:59.82

52wk High:62.32

52wk Low:14.79

Shares:73.27M

Float Shares:61.73M

Volume Ratio:1.73

T/O Rate:2.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6753

EPS(LYR):-1.8300

ROE:-15.31%

ROA:-11.00%

PB:5.01

PE(LYR):-33.42

Loading ...

Overview Company News Filings

Enliven Therapeutics posts ELVN-001 presentation outlining Phase 1 data in chronic myeloid leukemia

BUZZ-U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte

Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial

MT Newswires Live

Enliven Shares Climb on Positive Leukemia Drug Trial Data

Enliven up 15% to $42.50 after positive data from Phase 1 ENABLE trial

Enliven’s ELVN-001 shows efficacy in Phase 1 myeloid leukemia trial

BUZZ-Enliven rises as leukemia drug shows promising early-stage data

BRIEF-Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data

Enliven aligns with FDA on Phase 3 ENABLE-2 design for CML drug ELVN-001

Enliven Therapeutics - Reports Favorable Safety Profile With 161 Patients and 35 Week Median Treatment Duration

THOMSON REUTERS

Enliven Therapeutics - Reports 61% Overall Mmr and 48% Mmr at 24 Weeks in 80 Mg Qd Phase 1B Cohort

THOMSON REUTERS

Enliven Therapeutics - Enable-2 Pivotal Trial Expected to Initiate in Second Half of 2026

THOMSON REUTERS

Enliven Therapeutics - Reaches FDA Alignment on 80 Mg Qd Phase 3 Dose and 2L+ Patient Population for Enable-2 Trial

THOMSON REUTERS

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment With FDA on Key Phase 3 Trial Design Components

THOMSON REUTERS

Enliven Therapeutics - Increases Authorized Common Stock to 200 Mln Shares Effective June 9, 2026 - SEC Filing

THOMSON REUTERS

Enliven Therapeutics shareholders approved authorized common stock increase to 200 million shares at annual meeting

Enliven Therapeutics director Lori Anne Kunkel sells common shares worth $344,513.56

Enliven Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $60

THOMSON REUTERS

U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers

Enliven initiated with a Buy at Stifel

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/ELVN/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELVN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELVN\",,,,,undefined,":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":61.15,"timestamp":1787601600000,"preClose":59.82,"halted":0,"volume":1255203,"hourTrading":{"tag":"盘后","latestPrice":61.9,"preClose":61.15,"latestTime":"17:01 EDT","volume":180500,"amount":11037946.468999999,"timestamp":1787605316052,"change":0.75,"changeRate":0.012265,"amplitude":0.012265},"delay":0,"changeRate":0.022233366766967542,"floatShares":61725902,"shares":73270761,"eps":-1.67535,"marketStatus":"Post-Mkt","change":1.33,"latestTime":"08-24 19:22:58 EDT","open":59.77,"high":61.99,"low":59.47,"amount":76119564.22569,"amplitude":0.042126,"askPrice":61.9,"askSize":20000,"bidPrice":60.9,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.67535,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":59.82,"preHourTrading":{"tag":"盘前","latestPrice":59.82,"preClose":59.82,"latestTime":"09:29 EDT","volume":75677,"amount":4526473.849744,"timestamp":1787578199915,"change":0,"changeRate":0,"amplitude":0.050485},"postHourTrading":{"tag":"盘后","latestPrice":61.9,"preClose":61.15,"latestTime":"17:01 EDT","volume":180500,"amount":11037946.468999999,"timestamp":1787605316052,"change":0.75,"changeRate":0.012265,"amplitude":0.012265},"volumeRatio":1.728729,"impliedVol":0.6667,"impliedVolPercentile":0.5657},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELVN\",,,,,undefined,":{"symbol":"ELVN","floatShares":61725902,"roa":"-11.00%","roe":"-15.31%","lyrEps":-1.83,"volumeRatio":1.728729,"shares":73270761,"dividePrice":0,"high":61.99,"amplitude":0.042126,"preClose":59.82,"low":59.47,"week52Low":14.785,"pbRate":"5.01","week52High":62.32,"institutionHeld":0,"latestPrice":61.15,"committee":-0.970443,"eps":-1.67535,"divideRate":0,"volume":1255203,"delay":0,"ttmEps":-1.67535,"open":59.77,"prevYearClose":15.4,"prevWeekClose":59.82,"prevMonthClose":54.81,"prevQuarterClose":50.75,"fiveDayClose":59.535,"twentyDayClose":52.735,"sixtyDayClose":40.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELVN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"ELVN","fiscalQuarterEnding":"2026/06","expectedEps":-0.38,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2026-05-07","symbol":"ELVN","fiscalQuarterEnding":"2026/03","expectedEps":-0.44,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.38},{"market":"US","date":"2026-03-03","symbol":"ELVN","fiscalQuarterEnding":"2025/12","expectedEps":-0.42,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772514000000,"reportTimeType":"post","actualEps":-0.48},{"market":"US","date":"2025-11-12","symbol":"ELVN","fiscalQuarterEnding":"2025/09","expectedEps":-0.43,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2025-08-13","symbol":"ELVN","fiscalQuarterEnding":"2025/06","expectedEps":-0.53,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.49}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELVN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELVN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":14,"updateTime":1787112000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELVN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELVN","date":"2026-08-21","current":-35.705972,"percent":0.008245,"low":-43.197129,"twenty":-20.371092,"median":-13.127899,"eighty":-10.919864,"high":-6.665619,"avg":-15.531693,"sd":6.876255,"marketCap":4317113238},"quantilePoints":[{"date":"2023-02-24","current":-26.682642,"twenty":-26.682642,"median":-26.682642,"eighty":-26.682642,"marketCap":974023148},{"date":"2023-03-03","current":-24.8289,"twenty":-26.345598,"median":-24.559265,"eighty":-24.199752,"marketCap":906354172},{"date":"2023-03-10","current":-23.694186,"twenty":-25.199648,"median":-24.28963,"eighty":-23.806534,"marketCap":864932556},{"date":"2023-03-17","current":-24.997422,"twenty":-25.053596,"median":-24.508708,"eighty":-23.817768,"marketCap":912505897},{"date":"2023-03-24","current":-25.045524,"twenty":-25.045524,"median":-24.501056,"eighty":-23.817768,"marketCap":943264523},{"date":"2023-03-31","current":-23.847695,"twenty":-25.154418,"median":-24.513309,"eighty":-23.847695,"marketCap":898151871},{"date":"2023-04-06","current":-25.11086,"twenty":-25.119572,"median":-24.513309,"eighty":-23.847695,"marketCap":945725213},{"date":"2023-04-14","current":-20.962015,"twenty":-25.076502,"median":-24.390743,"eighty":-23.811629,"marketCap":789471394},{"date":"2023-04-21","current":-21.332253,"twenty":-25.048753,"median":-24.119928,"eighty":-22.848051,"marketCap":803415304},{"date":"2023-04-28","current":-20.635334,"twenty":-25.016663,"median":-23.926845,"eighty":-21.458569,"marketCap":777167943},{"date":"2023-05-05","current":-20.341321,"twenty":-24.896309,"median":-23.847695,"eighty":-21.260383,"marketCap":766094838},{"date":"2023-05-12","current":-20.851059,"twenty":-24.795534,"median":-23.81078,"eighty":-20.994683,"marketCap":785292584},{"date":"2023-05-19","current":-21.89907,"twenty":-24.705543,"median":-23.593073,"eighty":-21.113722,"marketCap":824762787},{"date":"2023-05-26","current":-21.462399,"twenty":-24.613192,"median":-22.720646,"eighty":-21.211975,"marketCap":808316869},{"date":"2023-06-02","current":-18.734285,"twenty":-24.559265,"median":-21.980633,"eighty":-20.954392,"marketCap":819006716},{"date":"2023-06-09","current":-21.377022,"twenty":-24.515759,"median":-21.83357,"eighty":-20.954392,"marketCap":934539290},{"date":"2023-06-16","current":-18.254642,"twenty":-24.497376,"median":-21.673899,"eighty":-20.758384,"marketCap":798038170},{"date":"2023-06-23","current":-20.812737,"twenty":-24.451411,"median":-21.642525,"eighty":-20.734427,"marketCap":909870413},{"date":"2023-06-30","current":-18.32988,"twenty":-24.28963,"median":-21.616844,"eighty":-20.341321,"marketCap":801327354},{"date":"2023-07-07","current":-17.361189,"twenty":-24.217728,"median":-21.517191,"eighty":-20.09872,"marketCap":758979115},{"date":"2023-07-14","current":-17.135475,"twenty":-24.135893,"median":-21.462399,"eighty":-19.332427,"marketCap":749111564},{"date":"2023-07-21","current":-17.972499,"twenty":-24.119928,"median":-21.435107,"eighty":-18.517975,"marketCap":785703732},{"date":"2023-07-28","current":-16.984999,"twenty":-23.971833,"median":-21.377022,"eighty":-18.220785,"marketCap":742533197},{"date":"2023-08-04","current":-16.881547,"twenty":-23.922067,"median":-21.256028,"eighty":-17.820142,"marketCap":738010570},{"date":"2023-08-11","current":-16.491696,"twenty":-23.861932,"median":-21.016461,"eighty":-17.568094,"marketCap":720967464},{"date":"2023-08-18","current":-12.980214,"twenty":-23.847695,"median":-20.922018,"eighty":-17.248332,"marketCap":669117064},{"date":"2023-08-25","current":-13.578933,"twenty":-23.823753,"median":-20.812737,"eighty":-17.129832,"marketCap":699980398},{"date":"2023-09-01","current":-12.469308,"twenty":-23.815574,"median":-20.736061,"eighty":-17.000046,"marketCap":642780353},{"date":"2023-09-08","current":-12.908368,"twenty":-23.809931,"median":-20.564155,"eighty":-16.862737,"marketCap":665413464},{"date":"2023-09-15","current":-13.123907,"twenty":-23.739125,"median":-20.333094,"eighty":-16.776213,"marketCap":676524264},{"date":"2023-09-22","current":-10.154264,"twenty":-23.633518,"median":-19.996164,"eighty":-15.495828,"marketCap":523442131},{"date":"2023-09-29","current":-10.968521,"twenty":-23.474031,"median":-19.373808,"eighty":-13.527842,"marketCap":565416265},{"date":"2023-10-06","current":-11.511359,"twenty":-23.372472,"median":-19.044642,"eighty":-13.224491,"marketCap":593399020},{"date":"2023-10-13","current":-9.994605,"twenty":-22.593241,"median":-18.52738,"eighty":-13.107941,"marketCap":515211909},{"date":"2023-10-20","current":-10.130315,"twenty":-22.058041,"median":-18.391011,"eighty":-12.999373,"marketCap":522207598},{"date":"2023-10-27","current":-9.555545,"twenty":-22.040989,"median":-18.292261,"eighty":-12.964248,"marketCap":492578798},{"date":"2023-11-03","current":-9.731169,"twenty":-21.920278,"median":-17.972499,"eighty":-12.485274,"marketCap":501632043},{"date":"2023-11-10","current":-7.695346,"twenty":-21.89907,"median":-17.817321,"eighty":-12.245786,"marketCap":475295332},{"date":"2023-11-17","current":-6.952736,"twenty":-21.83357,"median":-17.803213,"eighty":-11.215991,"marketCap":429428758},{"date":"2023-11-24","current":-7.786797,"twenty":-21.720035,"median":-17.492856,"eighty":-10.958941,"marketCap":480943724},{"date":"2023-12-01","current":-7.513225,"twenty":-21.68071,"median":-17.309463,"eighty":-10.760965,"marketCap":464046815},{"date":"2023-12-08","current":-7.506552,"twenty":-21.671453,"median":-17.210713,"eighty":-10.505512,"marketCap":463634696},{"date":"2023-12-15","current":-7.893557,"twenty":-21.652352,"median":-17.121368,"eighty":-10.333081,"marketCap":487537640},{"date":"2023-12-22","current":-8.620858,"twenty":-21.63925,"median":-17.013213,"eighty":-10.031327,"marketCap":532458691},{"date":"2023-12-29","current":-9.721819,"twenty":-21.630859,"median":-16.994403,"eighty":-9.985025,"marketCap":600458446},{"date":"2024-01-05","current":-9.735164,"twenty":-21.621546,"median":-16.919166,"eighty":-9.908649,"marketCap":601282686},{"date":"2024-01-12","current":-7.653347,"twenty":-21.612141,"median":-16.825118,"eighty":-9.735164,"marketCap":472701330},{"date":"2024-01-19","current":-8.547461,"twenty":-21.544748,"median":-16.787499,"eighty":-9.657763,"marketCap":527925374},{"date":"2024-01-26","current":-10.90285,"twenty":-21.510766,"median":-16.702856,"eighty":-9.657763,"marketCap":673403638},{"date":"2024-02-02","current":-10.972911,"twenty":-21.471637,"median":-15.246862,"eighty":-9.711143,"marketCap":677730895},{"date":"2024-02-09","current":-10.282309,"twenty":-21.462504,"median":-13.618847,"eighty":-9.729299,"marketCap":635076503},{"date":"2024-02-16","current":-11.543409,"twenty":-21.454109,"median":-13.399317,"eighty":-9.734365,"marketCap":712967132},{"date":"2024-02-23","current":-10.609261,"twenty":-21.445153,"median":-13.291548,"eighty":-9.761506,"marketCap":655270370},{"date":"2024-03-01","current":-10.655968,"twenty":-21.434015,"median":-13.147855,"eighty":-9.803015,"marketCap":658155208},{"date":"2024-03-08","current":-10.275636,"twenty":-21.409359,"median":-13.10395,"eighty":-9.82474,"marketCap":634664384},{"date":"2024-03-15","current":-6.665619,"twenty":-21.384546,"median":-13.044078,"eighty":-9.733566,"marketCap":477151673},{"date":"2024-03-22","current":-10.431636,"twenty":-21.350161,"median":-12.972231,"eighty":-9.727429,"marketCap":746738233},{"date":"2024-03-28","current":-10.760874,"twenty":-21.310474,"median":-12.880428,"eighty":-9.732767,"marketCap":770306384},{"date":"2024-04-05","current":-12.135517,"twenty":-21.260383,"median":-12.485274,"eighty":-9.752725,"marketCap":868708833},{"date":"2024-04-12","current":-15.541291,"twenty":-21.211975,"median":-12.53879,"eighty":-9.795033,"marketCap":1112507764},{"date":"2024-04-19","current":-11.553574,"twenty":-21.113722,"median":-12.520461,"eighty":-9.82282,"marketCap":827051011},{"date":"2024-04-26","current":-10.971645,"twenty":-20.994683,"median":-12.453342,"eighty":-9.833917,"marketCap":785394226},{"date":"2024-05-03","current":-13.724364,"twenty":-20.956933,"median":-12.42141,"eighty":-9.861485,"marketCap":982444863},{"date":"2024-05-10","current":-15.627075,"twenty":-20.927476,"median":-12.477291,"eighty":-9.897956,"marketCap":1118648510},{"date":"2024-05-17","current":-14.069999,"twenty":-20.877259,"median":-12.55712,"eighty":-9.908649,"marketCap":1119943779},{"date":"2024-05-24","current":-13.579529,"twenty":-20.83573,"median":-12.880428,"eighty":-9.913987,"marketCap":1080903320},{"date":"2024-05-31","current":-13.31952,"twenty":-20.807747,"median":-12.919935,"eighty":-9.925997,"marketCap":1060207172},{"date":"2024-06-07","current":-11.936748,"twenty":-20.777985,"median":-12.852488,"eighty":-9.949337,"marketCap":950141299},{"date":"2024-06-14","current":-13.012238,"twenty":-20.738783,"median":-12.908368,"eighty":-9.978639,"marketCap":1035748089},{"date":"2024-06-21","current":-12.433128,"twenty":-20.734427,"median":-12.823141,"eighty":-9.991412,"marketCap":989652125},{"date":"2024-06-28","current":-13.857265,"twenty":-20.713737,"median":-12.852488,"eighty":-9.999395,"marketCap":1103010568},{"date":"2024-07-05","current":-12.734501,"twenty":-20.635334,"median":-12.852488,"eighty":-10.018554,"marketCap":1013640841},{"date":"2024-07-12","current":-14.217731,"twenty":-20.492975,"median":-12.947875,"eighty":-10.03452,"marketCap":1131702953},{"date":"2024-07-15","current":-14.619562,"twenty":-20.462644,"median":-12.964248,"eighty":-10.034701,"marketCap":1163687908},{"date":"2024-08-02","current":-14.595925,"twenty":-20.432313,"median":-12.972231,"eighty":-10.034882,"marketCap":1161806440},{"date":"2024-08-09","current":-12.834959,"twenty":-20.33803,"median":-12.964248,"eighty":-10.054109,"marketCap":1021637080},{"date":"2024-08-16","current":-13.556309,"twenty":-20.306761,"median":-12.945278,"eighty":-10.088634,"marketCap":1122828410},{"date":"2024-08-23","current":-13.060138,"twenty":-20.227193,"median":-12.964248,"eighty":-10.111156,"marketCap":1081732040},{"date":"2024-08-30","current":-12.672326,"twenty":-20.030349,"median":-12.961651,"eighty":-10.130701,"marketCap":1049610739},{"date":"2024-09-06","current":-12.495529,"twenty":-19.786892,"median":-12.919935,"eighty":-10.135876,"marketCap":1034967205},{"date":"2024-09-13","current":-12.73506,"twenty":-19.581572,"median":-12.931502,"eighty":-10.154517,"marketCap":1054806832},{"date":"2024-09-20","current":-13.157091,"twenty":-19.368165,"median":-12.8873,"eighty":-10.156457,"marketCap":1089762365},{"date":"2024-09-27","current":-13.755918,"twenty":-19.332427,"median":-12.959054,"eighty":-10.16247,"marketCap":1139361432},{"date":"2024-10-04","current":-14.548651,"twenty":-19.185713,"median":-12.995005,"eighty":-10.191351,"marketCap":1205021150},{"date":"2024-10-11","current":-15.381306,"twenty":-18.794475,"median":-13.012238,"eighty":-10.271051,"marketCap":1273987472},{"date":"2024-10-18","current":-15.980134,"twenty":-18.692904,"median":-13.06278,"eighty":-10.276971,"marketCap":1323586540},{"date":"2024-10-25","current":-16.527633,"twenty":-18.517975,"median":-13.077247,"eighty":-10.282309,"marketCap":1368934258},{"date":"2024-10-31","current":-16.191149,"twenty":-18.480356,"median":-13.117169,"eighty":-10.282309,"marketCap":1341064306},{"date":"2024-11-08","current":-16.539039,"twenty":-18.452142,"median":-13.127899,"eighty":-10.308998,"marketCap":1369879003},{"date":"2024-11-15","current":-14.288385,"twenty":-18.32988,"median":-13.147855,"eighty":-10.377785,"marketCap":1217570416},{"date":"2024-11-22","current":-14.569336,"twenty":-18.254642,"median":-13.191309,"eighty":-10.377785,"marketCap":1241511408},{"date":"2024-11-29","current":-13.978765,"twenty":-18.119213,"median":-13.257473,"eighty":-10.420866,"marketCap":1191186467},{"date":"2024-12-06","current":-13.330857,"twenty":-17.99507,"median":-13.275582,"eighty":-10.465191,"marketCap":1135975609},{"date":"2024-12-13","current":-13.187514,"twenty":-17.927356,"median":-13.313517,"eighty":-10.47358,"marketCap":1123760818},{"date":"2024-12-20","current":-13.112976,"twenty":-17.840832,"median":-13.307514,"eighty":-10.475365,"marketCap":1117409126},{"date":"2024-12-27","current":-13.021237,"twenty":-17.81638,"median":-13.27352,"eighty":-10.487821,"marketCap":1109591659},{"date":"2025-01-03","current":-13.703547,"twenty":-17.808856,"median":-13.27352,"eighty":-10.502895,"marketCap":1167734067},{"date":"2025-01-10","current":-13.84689,"twenty":-17.803213,"median":-13.275582,"eighty":-10.521478,"marketCap":1179948858},{"date":"2025-01-17","current":-12.60841,"twenty":-17.759951,"median":-13.27352,"eighty":-10.564579,"marketCap":1074413060},{"date":"2025-01-24","current":-12.637079,"twenty":-17.586904,"median":-13.268745,"eighty":-10.609261,"marketCap":1076856018},{"date":"2025-01-31","current":-12.195584,"twenty":-17.492856,"median":-13.225528,"eighty":-10.642623,"marketCap":1039234460},{"date":"2025-02-07","current":-12.883628,"twenty":-17.445832,"median":-13.157091,"eighty":-10.649204,"marketCap":1097865460},{"date":"2025-02-14","current":-12.327459,"twenty":-17.361189,"median":-13.147855,"eighty":-10.655968,"marketCap":1050472069},{"date":"2025-02-21","current":-12.310258,"twenty":-17.278427,"median":-13.123907,"eighty":-10.661306,"marketCap":1049006294},{"date":"2025-02-28","current":-11.553409,"twenty":-17.220118,"median":-13.115073,"eighty":-10.671914,"marketCap":984512194},{"date":"2025-03-07","current":-12.304524,"twenty":-17.210713,"median":-13.077247,"eighty":-10.692528,"marketCap":1048517702},{"date":"2025-03-14","current":-11.168896,"twenty":-17.203189,"median":-13.06278,"eighty":-10.70156,"marketCap":994299783},{"date":"2025-03-21","current":-11.515688,"twenty":-17.148642,"median":-13.044078,"eighty":-10.73075,"marketCap":1025172571},{"date":"2025-03-28","current":-11.840461,"twenty":-17.112904,"median":-13.012192,"eighty":-10.756253,"marketCap":1054085181},{"date":"2025-04-04","current":-11.025775,"twenty":-17.062118,"median":-12.992568,"eighty":-10.756253,"marketCap":981558632},{"date":"2025-04-11","current":-8.207404,"twenty":-17.020737,"median":-12.961651,"eighty":-10.671914,"marketCap":730655976},{"date":"2025-04-17","current":-8.845942,"twenty":-17.00757,"median":-12.919935,"eighty":-10.646572,"marketCap":787501109},{"date":"2025-04-25","current":-10.073474,"twenty":-16.992523,"median":-12.900829,"eighty":-10.506428,"marketCap":896780977},{"date":"2025-05-02","current":-10.926692,"twenty":-16.945499,"median":-12.87493,"eighty":-10.47358,"marketCap":972737836},{"date":"2025-05-09","current":-10.268015,"twenty":-16.896595,"median":-12.837758,"eighty":-10.456802,"marketCap":914099729},{"date":"2025-05-16","current":-9.22086,"twenty":-16.864245,"median":-12.824716,"eighty":-10.419165,"marketCap":874414177},{"date":"2025-05-23","current":-8.677544,"twenty":-16.841798,"median":-12.774982,"eighty":-10.35027,"marketCap":822891456},{"date":"2025-05-30","current":-9.179465,"twenty":-16.826999,"median":-12.740411,"eighty":-10.284647,"marketCap":870488636},{"date":"2025-06-06","current":-11.057788,"twenty":-16.804427,"median":-12.734501,"eighty":-10.282309,"marketCap":1048610043},{"date":"2025-06-13","current":-10.172958,"twenty":-16.787499,"median":-12.717951,"eighty":-10.278305,"marketCap":964701612},{"date":"2025-06-20","current":-13.417901,"twenty":-16.781856,"median":-12.734501,"eighty":-10.282309,"marketCap":1272419584},{"date":"2025-06-27","current":-13.386798,"twenty":-16.747999,"median":-12.73478,"eighty":-10.283478,"marketCap":1269470072},{"date":"2025-07-03","current":-12.895368,"twenty":-16.702856,"median":-12.73478,"eighty":-10.288155,"marketCap":1222867778},{"date":"2025-07-11","current":-14.170598,"twenty":-16.684047,"median":-12.73506,"eighty":-10.29197,"marketCap":1343797781},{"date":"2025-07-18","current":-14.518953,"twenty":-16.539039,"median":-12.769279,"eighty":-10.308998,"marketCap":1376832318},{"date":"2025-07-25","current":-13.654285,"twenty":-16.539039,"median":-12.823141,"eighty":-10.377785,"marketCap":1294835877},{"date":"2025-08-01","current":-11.701007,"twenty":-16.527633,"median":-12.814277,"eighty":-10.377785,"marketCap":1109606508},{"date":"2025-08-08","current":-11.13493,"twenty":-16.527633,"median":-12.763576,"eighty":-10.392743,"marketCap":1055925385},{"date":"2025-08-15","current":-11.683894,"twenty":-16.52193,"median":-12.73478,"eighty":-10.409257,"marketCap":1170901400},{"date":"2025-08-22","current":-11.727119,"twenty":-16.516227,"median":-12.729357,"eighty":-10.425771,"marketCap":1175233252},{"date":"2025-08-29","current":-12.034483,"twenty":-16.491696,"median":-12.666623,"eighty":-10.431636,"marketCap":1206035736},{"date":"2025-09-05","current":-11.827604,"twenty":-16.470258,"median":-12.655877,"eighty":-10.465191,"marketCap":1185303295},{"date":"2025-09-12","current":-11.774406,"twenty":-16.437524,"median":-12.642812,"eighty":-10.47358,"marketCap":1179972096},{"date":"2025-09-19","current":-11.777361,"twenty":-16.362242,"median":-12.617902,"eighty":-10.475365,"marketCap":1180268273},{"date":"2025-09-26","current":-10.976442,"twenty":-16.281259,"median":-12.614144,"eighty":-10.477125,"marketCap":1100004107},{"date":"2025-10-03","current":-11.774406,"twenty":-16.205977,"median":-12.604497,"eighty":-10.492153,"marketCap":1179972096},{"date":"2025-10-10","current":-12.584192,"twenty":-16.158355,"median":-12.584192,"eighty":-10.509962,"marketCap":1261124795},{"date":"2025-10-17","current":-12.856091,"twenty":-16.100826,"median":-12.570656,"eighty":-10.522555,"marketCap":1288373147},{"date":"2025-10-24","current":-12.146789,"twenty":-16.047431,"median":-12.55712,"eighty":-10.547691,"marketCap":1217290490},{"date":"2025-10-31","current":-14.168299,"twenty":-16.017711,"median":-12.59139,"eighty":-10.598091,"marketCap":1419876061},{"date":"2025-11-07","current":-10.816849,"twenty":-16.012848,"median":-12.55712,"eighty":-10.635951,"marketCap":1084010510},{"date":"2025-11-14","current":-12.003893,"twenty":-15.986677,"median":-12.54534,"eighty":-10.635951,"marketCap":1202970115},{"date":"2025-11-21","current":-12.98587,"twenty":-15.975572,"median":-12.55712,"eighty":-10.647888,"marketCap":1262317432},{"date":"2025-11-28","current":-13.187343,"twenty":-15.974431,"median":-12.598588,"eighty":-10.653262,"marketCap":1281902047},{"date":"2025-12-05","current":-13.065238,"twenty":-15.940212,"median":-12.601543,"eighty":-10.659972,"marketCap":1270032583},{"date":"2025-12-12","current":-11.459557,"twenty":-15.886602,"median":-12.584192,"eighty":-10.669596,"marketCap":1113949140},{"date":"2025-12-19","current":-10.183559,"twenty":-15.842118,"median":-12.556807,"eighty":-10.629278,"marketCap":989913247},{"date":"2025-12-26","current":-10.214086,"twenty":-15.803337,"median":-12.543135,"eighty":-10.536256,"marketCap":992880613},{"date":"2026-01-02","current":-9.402087,"twenty":-15.766837,"median":-12.530924,"eighty":-10.485339,"marketCap":913948681},{"date":"2026-01-09","current":-14.194709,"twenty":-15.757712,"median":-12.525083,"eighty":-10.474026,"marketCap":1379825120},{"date":"2026-01-16","current":-15.366918,"twenty":-15.766837,"median":-12.533872,"eighty":-10.476139,"marketCap":1493771968},{"date":"2026-01-23","current":-16.502494,"twenty":-15.873654,"median":-12.554602,"eighty":-10.477453,"marketCap":1604157978},{"date":"2026-01-30","current":-15.67218,"twenty":-15.873654,"median":-12.55712,"eighty":-10.482717,"marketCap":1523445627},{"date":"2026-02-06","current":-16.478073,"twenty":-15.974431,"median":-12.601543,"eighty":-10.495828,"marketCap":1601784085},{"date":"2026-02-13","current":-16.581863,"twenty":-16.012848,"median":-12.60841,"eighty":-10.513495,"marketCap":1611873129},{"date":"2026-02-20","current":-15.971338,"twenty":-16.047431,"median":-12.614144,"eighty":-10.522555,"marketCap":1552525812},{"date":"2026-02-27","current":-18.083755,"twenty":-16.148743,"median":-12.62937,"eighty":-10.547691,"marketCap":1757867529},{"date":"2026-03-06","current":-16.891565,"twenty":-16.308347,"median":-12.642812,"eighty":-10.598091,"marketCap":1751553891},{"date":"2026-03-13","current":-16.614748,"twenty":-16.467534,"median":-12.654701,"eighty":-10.635951,"marketCap":1722849696},{"date":"2026-03-20","current":-17.329857,"twenty":-16.467534,"median":-12.66092,"eighty":-10.647888,"marketCap":1797002200},{"date":"2026-03-27","current":-22.658572,"twenty":-16.515009,"median":-12.723654,"eighty":-10.654615,"marketCap":2349557951},{"date":"2026-04-02","current":-21.793521,"twenty":-16.527633,"median":-12.734501,"eighty":-10.659972,"marketCap":2259857342},{"date":"2026-04-10","current":-26.291786,"twenty":-16.580833,"median":-12.737874,"eighty":-10.669596,"marketCap":2726300509},{"date":"2026-04-17","current":-26.147611,"twenty":-16.691571,"median":-12.769279,"eighty":-10.687954,"marketCap":2711350408},{"date":"2026-04-24","current":-25.311395,"twenty":-16.770571,"median":-12.821028,"eighty":-10.700446,"marketCap":2624639819},{"date":"2026-05-01","current":-23.777371,"twenty":-16.840911,"median":-12.830625,"eighty":-10.720149,"marketCap":2465570739},{"date":"2026-05-08","current":-23.660577,"twenty":-16.902605,"median":-12.844269,"eighty":-10.735381,"marketCap":2453459912},{"date":"2026-05-15","current":-26.562713,"twenty":-16.992523,"median":-12.857068,"eighty":-10.751632,"marketCap":2623785073},{"date":"2026-05-22","current":-26.050943,"twenty":-17.071504,"median":-12.866232,"eighty":-10.770508,"marketCap":2573233968},{"date":"2026-05-29","current":-25.064398,"twenty":-17.140318,"median":-12.883628,"eighty":-10.779257,"marketCap":2475786054},{"date":"2026-06-05","current":-21.882792,"twenty":-17.206951,"median":-12.898098,"eighty":-10.796387,"marketCap":2161516533},{"date":"2026-06-12","current":-24.885587,"twenty":-17.289838,"median":-12.908368,"eighty":-10.823355,"marketCap":2458123620},{"date":"2026-06-18","current":-27.660244,"twenty":-17.423782,"median":-12.959054,"eighty":-10.834214,"marketCap":2732195877},{"date":"2026-06-26","current":-30.286918,"twenty":-17.681151,"median":-12.983042,"eighty":-10.842708,"marketCap":2991650947},{"date":"2026-07-02","current":-34.467224,"twenty":-17.803213,"median":-13.001182,"eighty":-10.859067,"marketCap":3404568943},{"date":"2026-07-10","current":-36.884736,"twenty":-17.91607,"median":-13.012238,"eighty":-10.862815,"marketCap":3643363566},{"date":"2026-07-17","current":-35.951661,"twenty":-18.010492,"median":-13.044125,"eighty":-10.872726,"marketCap":3551197220},{"date":"2026-07-24","current":-37.330067,"twenty":-18.254642,"median":-13.065238,"eighty":-10.89369,"marketCap":3687352049},{"date":"2026-07-31","current":-38.135905,"twenty":-18.489761,"median":-13.068026,"eighty":-10.901018,"marketCap":3766950256},{"date":"2026-08-07","current":-39.727657,"twenty":-19.292928,"median":-13.08062,"eighty":-10.904296,"marketCap":4208231547},{"date":"2026-08-14","current":-40.16068,"twenty":-19.893608,"median":-13.117169,"eighty":-10.914394,"marketCap":4254100383},{"date":"2026-08-21","current":-40.755551,"twenty":-20.371092,"median":-13.127899,"eighty":-10.919864,"marketCap":4317113238}],"updateTime":1787576555158},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELVN\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642808172","title":"Enliven Therapeutics posts ELVN-001 presentation outlining Phase 1 data in chronic myeloid leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2642808172","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642808172?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:51","pubTimestamp":1781185919,"startTime":"0","endTime":"0","summary":"Enliven outlined plans to start Phase 3 ENABLE-2 in second-line or later CML in 2H 2026, using an 80 mg once-daily dose.FDA end-of-Phase 1 feedback supported 80 mg as the Phase 3 dose, a 2L+ population, a physician’s-choice comparator of ATP-competitive TKIs.Phase 1b data showed 48% MMR by week 24 at 80 mg once daily; 55% MMR by week 24 in second- and third-line patients.Discontinuations due to adverse events ran 6% at 80 mg; 82% of patients remained on study at the data cutoff.Cash, cash equivalents, and marketable securities totaled $452 million as of March 31, 2026, providing runway into 1H 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL53yw6R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642704282","title":"BUZZ-U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2642704282","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642704282?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:13","pubTimestamp":1781183583,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, HumacyteWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nL6N42J0OS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORCL","BK4187","BK4543","IE00BN8TJ469.HKD","LU0949170772.SGD","LU1935042991.SGD","LU1642822529.SGD","LU0208291251.USD","IE00BMPRXQ63.HKD","LU0501845795.SGD","IE00BF5LJ272.USD","LU0957808578.USD","LU0300736492.USD","LU0234570918.USD","PCT","BK4090","SNK","LU0980610538.SGD","BK4097","IE00B19Z3581.USD","BK4614","IE00BFMHRM44.USD","LU0289960550.SGD","LU0965508806.USD","IE00B775SV38.USD","LU1152091168.USD","LU2458330169.SGD","LU0738911758.USD","BBYY","IE0004445239.USD","LU1303367103.USD","LU1852331112.SGD","BK4551","LU0323591593.USD","LU1051768304.USD","SPAL","LU1003077747.HKD","LU0251143458.SGD","LU0348816934.USD","LU0719512351.SGD","LU1880383366.USD","LU0348723411.USD","LU1282648689.USD","LU0314106906.USD","UUUG","LU0417517546.SGD","LU1035773651.USD","LU0821914370.USD","LU0157215616.USD","LU0651947912.USD","LU1935042215.USD","LU0047713382.USD","BHP","LU1008478684.HKD","LU1267930227.SGD","LU1366192091.USD","LU1429558221.USD","LU0965509010.AUD","LU2226246903.HKD","BK4527","SG9999003800.SGD","GD","IE00BLSP4239.USD","LU2458330243.SGD","LU0130102774.USD","BABA","BK4528","LU0198837287.USD","ORCX","AA","IE0009356076.USD","LU0661504455.SGD","IE00BMPRXR70.SGD","LU0889565833.HKD","LU1048596156.SGD","BK4524","LU2236285917.USD","LU1803068979.SGD","SPCF","BK4505","LU2237957811.SGD","LU1769817096.USD","LU2087625088.SGD","SG9999011175.SGD","LU1046422090.SGD","HUMA","LU1201861249.SGD","LU0965509101.SGD","LU2896262040.SGD","LU0861579265.USD","LU2054465674.USD","LU1242518857.USD","LU2098885051.SGD","SG9999001424.SGD","LU0553294199.USD","SPCH","LU2237957902.USD","BK4558","BK4607","LU0234572021.USD","LU0918141705.HKD","LU1989772923.USD","LU0175139822.USD","LU0651946864.USD","LU1934455277.USD","BK4516","BK4563","LU0979878070.USD","LU0328353924.USD","LU1934455194.USD","BK4156","BK4548","BK4153","BK4550","LU1720051108.HKD","LU0128525689.USD","09988","ELVN","LU0353189680.USD","LU1366333091.USD","LU1242518931.SGD","LU1989772840.SGD","LU2108987350.USD","LU1720051017.SGD","LU2357305700.SGD","LU2360106780.USD","LU0310800965.SGD","LU1769817179.HKD","SPCX","LU1823568750.SGD","IE00B5949003.HKD","BK4535","LU0068578508.USD","BK4504","LU0476273544.USD","BK4089","GH","BK4587","BK4565","LU0052756011.USD","RIO","IE00B19Z3B42.SGD","LU0348814723.USD","LU1935043023.USD","BABX","BK4533","ORCU","BK4581","BK4134","BK4538","BNAI","LU0648001328.SGD","BK4531","LU1051769294.HKD","LU1048588211.SGD","LU2148611432.USD","BK4575","BK4566","LU1069347547.HKD","LU1934455863.HKD","LU2746668974.SGD","LU0072462343.USD","BABU","LOFF","LU1489326972.SGD","LU0106959298.USD","IE0002270589.USD","LU1935043536.SGD","LU0320765489.SGD","BABW","LU0072913022.USD","LU1935042488.USD","LU1152091754.HKD","LU0456842615.SGD","IE00B3S45H60.SGD","LU2543165471.USD","BK4502","BK4196","KBAB","IE00BBT3K403.USD","LU0109392836.USD","BK4579","LU0067412154.USD","LU1688375341.USD","BK4124","LU1989764664.SGD","LU0256863811.USD","LU0797268264.HKD","BK4220","LU0056508442.USD","LU2250418816.HKD","LU1235294995.USD","BK4606","LU0300736062.USD","IE00BMPRXN33.USD","LU0070302665.USD","LU1691799644.USD","LU0353189763.USD","IE00BLSP4452.SGD","SPCU","ORCS","LU1105468828.SGD","LU0433182093.SGD","LU0880133367.SGD","DXC","LU0965509283.SGD","LU2326559502.SGD","BK4007","BK4534","BK4139","BK4585","IE00B7SZLL34.SGD","LU1037948897.HKD","LU1435385759.SGD","LU1506573853.SGD","LU0444973449.USD","LU1515016050.SGD","LU1548497426.USD","LU0985489474.SGD","LU0170899867.USD","LU0210536198.USD","LU2746668461.USD","LU0918141887.USD","BK4168","BK4588","LU0545039389.USD","LU1815336760.USD","LU1046421795.USD","IE00B0JY6N72.USD","LU0081259029.USD","DAN","LU0878866978.SGD","BK4503","LU1037948541.HKD","LU0444971666.USD","LU2860962120.EUR","LU1989764748.USD","UUUU","BABO","BK4122","LU0082616367.USD","BK4554","ALBmain","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642827432","title":"Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642827432","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642827432?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:11","pubTimestamp":1781183479,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics  said Thursday that it has reached alignment with the US Food and Drug Administration on the 80 mg once daily dose of ELVN-001 in a planned late-stage trial for chronic myeloid leukemia.The company said the trial will enroll patients with chronic myeloid leukemia who have previously been treated with one or more tyrosine kinase inhibitors, or TKIs, and will receive either ELVN-001 or the physician's choice of ATP-competitive TKI.Enliven said additional details on late-stage trial design will be finalized after another meeting with the FDA in Q3, with the study set to begin in the second half of this year.Enliven also published data from the first phase of the study. In the 80 mg QD phase 1b cohort, the overall major molecular response by 24 weeks was 61%, with 67% in patients who had previously received one or two unique TKIs, it said.Shares of the company were up 22% in recent Thursday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","ELVN","LABU","LENZ","BK4007","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282119","title":"Enliven Shares Climb on Positive Leukemia Drug Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282119","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282119?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:00","pubTimestamp":1781182800,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics's shares jumped after the company released positive early data on the latest trial of its leukemia drug and said regulators green lit the design of a final large-scale study.The stock was up 26% at $46.60 in premarket trading. Shares had already doubled year-to-date when the market closed Wednesday.The clinical-stage biopharmaceutical company said before the opening bell that in the phase 1 clinical trial evaluating ELVN-001, its lead drug candidate, up to 61% of patients with previously treated chronic myeloid leukemia saw cancer markers drop significantly. Only 6% of patients stopped the treatment due to side effects.Chief Medical Officer Helen Collins said the results were promising and showcase the consistency of ELVN-001's overall profile.At the end of the trial, Enliven met with the Food and Drug Administration and reached an alignment with the agency on the planned daily dose and patient types to be used in a planned phase 3 trial.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Enliven Shares Climb on Positive Leukemia Drug Trial Data","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642897284","title":"Enliven up 15% to $42.50 after positive data from Phase 1 ENABLE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642897284","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642897284?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:17","pubTimestamp":1781180232,"startTime":"0","endTime":"0","summary":"08:15 EDT Enliven (ELVN) up 15% to $42.50 after positive data from Phase 1 ENABLE trial Published first on TheFly – the ultimate source for real-ti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-up-15-to-42-50-after-positive-data-from-phase-1-enable-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-up-15-to-42-50-after-positive-data-from-phase-1-enable-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642284870","title":"Enliven’s ELVN-001 shows efficacy in Phase 1 myeloid leukemia trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642284870","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642284870?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:11","pubTimestamp":1781179908,"startTime":"0","endTime":"0","summary":"Enliven (ELVN) Therapeutics presented updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with previously ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enlivens-elvn-001-shows-efficacy-in-phase-1-myeloid-leukemia-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enlivens-elvn-001-shows-efficacy-in-phase-1-myeloid-leukemia-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642231281","title":"BUZZ-Enliven rises as leukemia drug shows promising early-stage data","url":"https://stock-news.laohu8.com/highlight/detail?id=2642231281","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642231281?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:07","pubTimestamp":1781179646,"startTime":"0","endTime":"0","summary":"BUZZ-Enliven rises as leukemia drug shows promising early-stage data** Shares of biotech firm Enliven Therapeutics ELVN.O rise 3.59% to $38.33 premarket** Co says its experimental drug ELVN-001 for chronic myeloid leukemia, a type of blood cancer, showed encouraging early-stage results** Says 61% of patients in key group saw major disease reduction; ~50% achieved this within 24 weeks** Adds patients with prior one or two treatments showed higher 67% response rate** Co says study enrolled 161 patients, most pretreated; only 6% discontinued due to side effects** Says FDA agreed to key design for late-stage study and use of 80 mg dose vs standard treatments** As of last close, stock up about two-fold YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nL4N42J0XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281128","title":"BRIEF-Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281128","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281128?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:02","pubTimestamp":1781179378,"startTime":"0","endTime":"0","summary":"BRIEF-Enliven Therapeutics Announces Updated Positive Phase 1 Clinical DataJune 11 (Reuters) - Enliven Therapeutics Inc ELVN.O:ENLIVEN THERAPEUTICS ANNOUNCES UPDATED POSITIVE PHASE 1 CLINICAL DATA AND","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA65VTNK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281906","title":"Enliven aligns with FDA on Phase 3 ENABLE-2 design for CML drug ELVN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281906","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281906?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:01","pubTimestamp":1781179310,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics presented updated Phase 1 data on ELVN-001 for previously treated chronic myeloid leukemia at the EHA 2026 Congress.The update showed meaningful molecular responses across treatment lines, with a stronger response trend in earlier-line patients.Safety remained broadly favorable, supporting long-term use, with limited treatment discontinuations due to adverse events.FDA alignment set 80 mg once-daily as the Phase 3 dose, defining the target population for the pivotal ENABLE-2 trial.ENABLE-2 is expected to start in the second half of 2026, comparing ELVN-001 with physician’s choice of an ATP-competitive TKI.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL9ZZPR4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642819962","title":"Enliven Therapeutics - Reports Favorable Safety Profile With 161 Patients and 35 Week Median Treatment Duration","url":"https://stock-news.laohu8.com/highlight/detail?id=2642819962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642819962?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA65VTNK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642819512","title":"Enliven Therapeutics - Reports 61% Overall Mmr and 48% Mmr at 24 Weeks in 80 Mg Qd Phase 1B Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2642819512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642819512?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA65VTNK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281966","title":"Enliven Therapeutics - Enable-2 Pivotal Trial Expected to Initiate in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281966?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA65VTNK:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281960","title":"Enliven Therapeutics - Reaches FDA Alignment on 80 Mg Qd Phase 3 Dose and 2L+ Patient Population for Enable-2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281960?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA65VTNK:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642028165","title":"Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment With FDA on Key Phase 3 Trial Design Components","url":"https://stock-news.laohu8.com/highlight/detail?id=2642028165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642028165?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:00","pubTimestamp":1781179203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA65VTNK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642447319","title":"Enliven Therapeutics - Increases Authorized Common Stock to 200 Mln Shares Effective June 9, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2642447319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642447319?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:01","pubTimestamp":1781085712,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nFWN42I0BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642447554","title":"Enliven Therapeutics shareholders approved authorized common stock increase to 200 million shares at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642447554","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642447554?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:01","pubTimestamp":1781085668,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics held its annual shareholder meeting on June 9, 2026.Investors backed an increase in authorized common stock to 200 million shares from 100 million.The charter amendment was executed through a filed certificate of amendment, effective June 9, 2026.Shareholders supported holding future advisory votes on executive pay every year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL6kD5vh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642908774","title":"Enliven Therapeutics director Lori Anne Kunkel sells common shares worth $344,513.56","url":"https://stock-news.laohu8.com/highlight/detail?id=2642908774","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642908774?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:49","pubTimestamp":1781038188,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics director Lori Anne Kunkel sold 10,000 common shares on June 5, 2026.Sales priced at USD 34.28, USD 35.36, USD 35.82 per share, based on weighted-average prices.She held 51,884 common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL5Y89Mn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics director Lori Anne Kunkel sells common shares worth $344,513.56","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642246403","title":"Enliven Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2642246403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642246403?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:17","pubTimestamp":1781003825,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nFWN42H0AD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642450257","title":"U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers","url":"https://stock-news.laohu8.com/highlight/detail?id=2642450257","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642450257?lang=en_us&edition=fundamental","pubTime":"2026-06-09 15:46","pubTimestamp":1780991198,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers June 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apple, Lennar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nL4N42H0KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ULTA","ZVRA","AAPB","AAPL","DGE.UK","EQR","AAPD","AAPU","AJG","ODFL","AAPX","PAR","AAPY","ECL","PODD","DXCM","LMND","CAR","TNGX","ATO","GMRS","APLX","ARCB","EROK","FICO","APLD","GPN","LOPE","GOOG","TOL","GSHD","AAPW","LMNX","DEO","BRO","USJW.SI","GHM","ELVN","BBUC","FFIV","CLF","FVR","MTN","LEN","AU","PFS","CDNS","CPB","BWIN","APLZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642243142","title":"Enliven initiated with a Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2642243142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642243142?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:18","pubTimestamp":1780949906,"startTime":"0","endTime":"0","summary":"Stifel initiated coverage of Enliven (ELVN) with a Buy rating and $60 price target The company’s ELVN-001 is “uniquely positioned” as a complement ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enliven-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enliven-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","BK4127","SF","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":104,"code":"91000000","status":"200"}]}}